Cassava

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA

Retrieved on: 
Tuesday, March 19, 2024
Titan, Cassava Sciences, Plaintiff, Class, Advertising, Data management, Court, Cassava

WHAT TO DO NEXT: To join the Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA

Retrieved on: 
Sunday, March 17, 2024
Titan, Cassava Sciences, Plaintiff, Class, Advertising, Data management, Court, Cassava

WHAT TO DO NEXT: To join the Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA

Retrieved on: 
Friday, March 15, 2024
Titan, Cassava Sciences, Plaintiff, Class, Advertising, Data management, Court, Cassava

WHAT TO DO NEXT: To join the Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

Retrieved on: 
Tuesday, April 2, 2024
Failure, Certification, Cassava Sciences, Ethics, Complaint, Suite, Data management, Cassava, Security (finance)

Investors who purchased the Company's securities between August 18, 2022 and October 12, 2023, inclusive (the “Class Period”), are encouraged to contact the firm before April 2, 2024.

Key Points: 
  • Investors who purchased the Company's securities between August 18, 2022 and October 12, 2023, inclusive (the “Class Period”), are encouraged to contact the firm before April 2, 2024.
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Cassava Sciences, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 2, 2024 deadline.

Retrieved on: 
Monday, April 1, 2024
Reputational damage, Cassava Sciences, False, Data management, Cassava

LOS ANGELES, April 01, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) investors that a lawsuit was filed on behalf of investors that purchased Cassava securities between August 18, 2022 and October 12, 2023, inclusive (the “Class Period”).

Key Points: 
  • LOS ANGELES, April 01, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) investors that a lawsuit was filed on behalf of investors that purchased Cassava securities between August 18, 2022 and October 12, 2023, inclusive (the “Class Period”).
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 310-692-8883 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action – SAVA

Retrieved on: 
Sunday, March 31, 2024
Titan, Cassava Sciences, Class, Advertising, Data management, Court, Cassava

WHAT TO DO NEXT: To join the Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA

Retrieved on: 
Sunday, March 31, 2024
Cassava Sciences, Prior, Initiative, Science, District court, Patient, City University, Journal, Biomarker, News, Ext, LLP, Cassava, Complaint, Person, Neurobiology of Aging, Cognition, Safety, Pomerantz, Action Replay, Data management, FDA, Court, Pharmaceutical industry

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).

Key Points: 
  • NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Sunday, March 31, 2024
Cassava Sciences, Cassava, Complaint, Data management, Court, Person

Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/SAVA .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/SAVA .
  • The Complaint alleges that throughout the Class Period Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Holzer & Holzer, LLC Reminds Shareholders of April 2, 2024 Lead Plaintiff Deadline in Cassava Sciences, Inc. (SAVA) Class Action – Nationally Ranked Investors’ Rights Firm Encourages Investors With Significant Losses to Contact the Firm

Retrieved on: 
Thursday, March 28, 2024
Loss, Cassava Sciences, Fraud, Data management, ISS, Cassava

ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA).

Key Points: 
  • ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA).
  • The deadline to ask the court to be appointed lead plaintiff in the case is April 2, 2024.
  • Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021 and 2022, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation.
  • Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 26, 2024
Apoptosis, Patient, AMX0035, Science, New York Community Bank, NYCB, P.C, Initiative, ACL, Scientific misconduct, IBD, Confidentiality, Safety, Injury, Data management, Food, Signature, Cassava Sciences, ALS, Alzheimer's disease, Defendant, Food and Drug Administration, Journal, Amyotrophy, News, Prescription, Amylyx Pharmaceuticals, Dentist, FDA, City University, Biomarker, Dermatology, Complaint, Investor's Business Daily, Neurobiology of Aging, Cognition, Assumption, Category, BBC World Service, Evercore, Cassava, Pharmaceutical industry

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD